Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Tofacitinib versus methotrexate in rheumatoid arthritis.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators.

N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476.

2.

Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosis.

Maslyanskiy A, Lazareva N, Olinek P, Schierack P, Hentschel C, Cuccato J, Bogdanos DP, Lapin SV, Roggenbuck D.

J Immunol Res. 2014;2014:516593. doi: 10.1155/2014/516593. Epub 2014 May 4.

3.

Effects of rituximab therapy on elastic properties of vascular wall in patients with progressive systemic sclerosis.

Maslyanskiy AL, Lapin SV, Kolesova EP, Penin IN, Cheshuina MD, Feist E, Konradi AO.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-228. Epub 2014 Jan 30. No abstract available.

PMID:
24480389
4.

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.

Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A, Skoromets A, Bar-Or A.

ISRN Neurol. 2013 Sep 10;2013:748127. doi: 10.1155/2013/748127. eCollection 2013.

5.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk